0002001011-24-000079.txt : 20240830 0002001011-24-000079.hdr.sgml : 20240830 20240830205618 ACCESSION NUMBER: 0002001011-24-000079 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240828 FILED AS OF DATE: 20240830 DATE AS OF CHANGE: 20240830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reardon Andrew CENTRAL INDEX KEY: 0001950232 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 241271633 MAIL ADDRESS: STREET 1: C/O LIGAND PHARMACEUTICALS INCORPORATED STREET 2: 3911 SORRENTO VALLEY BLVD, SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-08-28 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001950232 Reardon Andrew 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 0 1 0 0 CLO & Secretary 0 Common Stock 2024-08-28 4 M 0 1500 52.27 A 24034 D Common Stock 2024-08-28 4 S 0 1500 106.3937 D 22534 D Non-Qualified Stock Option (right to buy) 52.27 2024-08-28 4 M 0 1500 0.0 D 2032-08-01 Common Stock 1500 61444 D The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $106.3200 to $106.4700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. /s/ Andrew Reardon 2024-08-30